Desirability and feasibility of a vaccine against cytomegalovirus.
about
Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complexThe immunological underpinnings of vaccinations to prevent cytomegalovirus disease.Prevention of Primary Cytomegalovirus Infection in Pregnancy.Improvement of cytomegalovirus pp65 DNA vaccine efficacy by co-administration of siRNAs targeting BAK and BAXInhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense.Human cytomegalovirus tropism for mucosal myeloid dendritic cells.Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodiesReduced frequencies of polyfunctional CMV-specific T cell responses in infants with congenital CMV infectionComplete protection of mice against lethal murine cytomegalovirus challenge by immunization with DNA vaccines encoding envelope glycoprotein complex III antigens gH, gL and gONovel heparan sulfate-binding peptides for blocking herpesvirus entry.A dynamic transmission model with age-dependent infectiousness and reactivation for cytomegalovirus in the United States: Potential impact of vaccination strategies on congenital infection.Limits and patterns of cytomegalovirus genomic diversity in humans.Genetic identification of cytomegaloviruses in a rural population of Côte d'Ivoire.Activation of Innate and Adaptive Immunity by a Recombinant Human Cytomegalovirus Strain Expressing an NKG2D LigandVaccine-Derived Neutralizing Antibodies to the Human Cytomegalovirus gH/gL Pentamer Potently Block Primary Cytotrophoblast Infection.The immunology of human cytomegalovirus latency: could latent infection be cleared by novel immunotherapeutic strategies?Awareness of Cytomegalovirus Infection among Pregnant Women in Geneva, Switzerland: A Cross-sectional Study.Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection agaModeling the potential impact of vaccination on the epidemiology of congenital cytomegalovirus infectionInduction of innate immune signatures following polyepitope protein-glycoprotein B-TLR4&9 agonist immunization generates multifunctional CMV-specific cellular and humoral immunityCytomegalovirus in the neonate: immune correlates of infection and protectionRat Cytomegalovirus Vaccine Prevents Accelerated Chronic Rejection in CMV-Naïve Recipients of Infected Donor Allograft Hearts.Vaccination against a virus-encoded cytokine significantly restricts viral challengeProduction of Cytomegalovirus Dense Bodies by Scalable Bioprocess Methods Maintains Immunogenicity and Improves Neutralizing Antibody Titers.Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?Molecular and biological characterization of a new isolate of guinea pig cytomegalovirus.Quantification of cytomegalovirus viral load.Cytomegalovirus infection in liver transplant recipients: updates on clinical managementTreatment of CMV infection after allogeneic hematopoietic stem cell transplantation.Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection.Treatment and prevention of cytomegalovirus infection in heart and lung transplantation: an update.Treatment of perinatal viral infections to improve neurologic outcomes.Increasing Complexity of Vaccine Development.Identification of a Continuous Neutralizing Epitope within UL128 of Human Cytomegalovirus.The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.APOBEC3A is Upregulated by Human Cytomegalovirus in the Maternal-Fetal Interface, Acting as an Innate Anti-HCMV Effector.Infectious reactivation of cytomegalovirus explaining age- and sex-specific patterns of seroprevalenceProgramming CMV for vaccine vector design.A Bioreactor Method to Generate High-titer, Genetically Stable, Clinical-isolate Human Cytomegalovirus.
P2860
Q21089588-0F4186BC-9EA3-4ED9-B365-AB5C77628874Q27692570-A53192F8-0073-41CD-B362-FDA9FF6F85C9Q30666266-2BD77226-3D64-441F-92EB-9696E6F4C2CCQ33744024-9D0958CB-D6F4-4D04-9E10-A433CEDD3773Q34047484-2C89D34B-B899-4E07-BD90-830E1ED38560Q34422068-199BB2C7-D447-4C6F-B20F-D35C9DC42C39Q34753135-73C4CB48-2C20-4796-9E72-08DE8A52DA0CQ35196400-04D224AF-A75B-4FB6-BB88-9D0FF4373F4CQ35214272-F8C8C2BD-3ED5-43B9-ACA8-9EC282D7448AQ35636214-50F5B8E9-B12F-4851-960B-5B0E6706B6D4Q35886919-166B7C60-C031-4E95-912F-D6FCAD8ACD43Q35910248-FF5E56E8-E9C9-4CC8-94DC-D0C0038AF8C3Q36126229-3CF2B109-0C1A-486D-A7E0-DB331C1E233CQ36210368-03BE185C-26BB-43FB-BA19-7E55BCEA2DE2Q36281094-B4C8D942-1B59-4F91-A55E-68FF46A93679Q36302615-4B72F9E9-D7C2-4504-9483-CB78CE8EAF82Q36403590-B65CF3A2-2D41-4D59-8205-8578AE5CBAC2Q36430938-2D83C100-08B9-421A-9E3C-C9468D30CFBFQ36633558-E3EBCA1A-4CF6-446A-9239-3257069A811CQ36830632-38B59B33-5D27-4CAF-AE9D-E28CA5C392AEQ36977623-2AB239FD-35C4-4185-B26D-F57E8D60C053Q37140130-3782CBAA-E020-4E77-9F0A-92ADAA360EABQ37222032-B477E556-7B1F-4A29-B07A-E01ABD07F44DQ37252720-340FB721-1280-4E1E-B07A-5AB1E5C5B6AAQ37409233-C8B8A308-8B02-4465-BAFC-89DC44EAED98Q37574334-9E6E4475-126A-4962-9192-EB4201CF210DQ37611802-1294DF0E-B269-40C2-9991-F29418083BD0Q38171537-E0F6117E-540B-4C3A-B4B5-620EAECC7E3BQ38242802-73DA189D-7D9F-480F-8323-C21BA3F9FCC1Q38797660-6DCE06D5-7663-4A0C-ACA0-FA287D574C4BQ38802522-5C155E4E-1D17-4A07-A18D-95FBEE0EB8C2Q38875887-C7D4A068-4B2E-48F8-BFD0-44FB69170AF7Q38965659-D3D8C7AF-2625-403F-ACC3-3A66A912D302Q38990899-14D557EB-5699-4A5F-98FD-F053F24E1C48Q40375876-B52514D9-E04A-4DAF-942E-74A50C215442Q40483485-16A59431-C0FE-4AA5-A588-B3EA8D00F54CQ41928866-54835456-FCF2-4336-BA3A-C2EAF352D049Q41929983-014A37EE-3896-440B-9BFC-3BB5F6F4B6CEQ42270816-FD5B6820-F0CA-4D4A-9155-B244A0931A43Q46065213-227CDB99-5E19-4D36-8071-502195F7723F
P2860
Desirability and feasibility of a vaccine against cytomegalovirus.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Desirability and feasibility of a vaccine against cytomegalovirus.
@en
type
label
Desirability and feasibility of a vaccine against cytomegalovirus.
@en
prefLabel
Desirability and feasibility of a vaccine against cytomegalovirus.
@en
P2093
P2860
P1433
P1476
Desirability and feasibility of a vaccine against cytomegalovirus.
@en
P2093
Edward Mocarski
Mark Schleiss
Paul Griffiths
Robert Pass
Stephanie Bialek
P2860
P304
P356
10.1016/J.VACCINE.2012.10.074
P407
P478
31 Suppl 2
P577
2013-04-01T00:00:00Z